Deal Tracker · Regions

Latin America pharma deals

17 pharma deals in Latin America tracked by EPT — licensing, distribution & investment. Most active: AMA Medical Manufacturing, Samsung Bioepis, A.C.Camargo Cancer Center & Afreximbank. Latest: Laboratorios Siegfried → Laboratorio Chile (M&A / Acquisition, 19 Nov 2026).

17
deals tracked
16
announced in 2026
$148.6m
disclosed value (3 deals)
24%
licensing, the top deal type
  • EPT has tracked 17 Latin America pharma deals (2022–2026), 16 of them announced in 2026.
  • The most common structures are licensing (24%), distribution (18%) & investment (12%).
  • The countries that appear most often are Brazil (9), Argentina (4), Mexico (4) & South Korea (4).
  • Values were disclosed for 3 of 17 deals, totalling $148.6m; the largest is Orchid Pharma → Laboratorio Libra ($80m, 24 Oct 2026).
  • The most active companies: AMA Medical Manufacturing (2) & Samsung Bioepis (2).

Most active companies

AMA Medical Manufacturing (2) · Samsung Bioepis (2)

Countries involved

Brazil (9) · Argentina (4) · Mexico (4) · South Korea (4) · Chile (3) · Switzerland (3)

Largest disclosed deals

Questions

How many Latin America pharma deals has EPT tracked?
17 as of 19 Nov 2026, covering 2022–2026; 16 were announced in 2026. The most recent is Laboratorios Siegfried → Laboratorio Chile (M&A / Acquisition, 19 Nov 2026).
What types of Latin America pharma deals are most common?
Licensing: 4 (24%); Distribution: 3 (18%); Equity / Investment: 2 (12%); M&A / Acquisition: 2 (12%).
Which companies are most active in Latin America pharma deals?
AMA Medical Manufacturing (2 deals), Samsung Bioepis (2 deals).
What is the largest disclosed Latin America pharma deal?
Orchid Pharma → Laboratorio Libra: $80m (Licensing, 24 Oct 2026); Shanghai Henlius Biotech → Eurofarma: $50.5m (Licensing, 11 May 2022); Laboratorios Siegfried → Laboratorio Chile: $18.1m (M&A / Acquisition, 19 Nov 2026). Values are as announced by the parties.
Which countries appear most in Latin America pharma deals?
Brazil (9), Argentina (4), Mexico (4), South Korea (4), Chile (3), Switzerland (3) — counting where the parties are based and the markets the deals cover.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)